A summary in Thursday's BIO SmartBrief incorrectly stated that a new amphetamine from New River Pharmaceuticals and to be sold by Shire Pharmaceuticals might have difficulty making it to market. New River has presented positive data on the drug, NRP104, but some investors and analysts say the FDA and Drug Enforcement Administration may be less lenient in their classifications because of fears of drug abuse. SmartBrief regrets the error.

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA